Actinium PRRT (Peptide Receptor Radionuclide Therapy) is a type of targeted therapy used in the treatment of certain types of cancer, particularly neuroendocrine tumors (NETs). PRRT involves the use of a radioactive substance combined with a targeting molecule (peptide) that specifically binds to receptors on the surface of cancer cells.
The radioactive substance most commonly used in Actinium PRRT is Actinium-225 (Ac-225), which emits alpha particles. Alpha particles have high energy and can travel only a short distance in tissue, making them effective in delivering radiation to targeted cancer cells while minimizing damage to surrounding healthy tissues.